Form 4: BioLife Solutions EVP Aby J. Mathew Reports Stock Grants

EVP and Chief Scientific Officer of BioLife Solutions, Aby J. Mathew, reports the acquisition of common stock through restricted stock grants.

Summary

• On March 18, 2025, Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., reported the acquisition of 22,919 shares of common stock through a restricted stock grant.
• These shares were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vest 25% on the first anniversary of the grant date, followed by quarterly installments over the next 12 quarters.
• Additionally, Mr. Mathew acquired 36,645 shares of common stock through the 2013 Performance Incentive Plan, which vested at 175% based on the company's total shareholder return from January 1, 2023, to December 31, 2024, compared to its peers.
• Following these transactions, Mr. Mathew directly owns 320,165 shares of BioLife Solutions Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reports standard stock grants to an executive, which is generally viewed as a positive sign of aligning management interests with shareholders. There are no explicitly negative aspects mentioned.

Positives

• The grants of restricted stock align Mr. Mathew's interests with those of the shareholders, incentivizing him to improve company performance.
• The vesting schedule of the 2023 plan encourages long-term commitment from Mr. Mathew.

Industry Context

Stock grants to executives are a common practice in the biotech industry to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in publicly traded companies, particularly in the biotech sector.
• Companies like Thermo Fisher Scientific and Danaher Corporation also utilize stock-based compensation to incentivize their executives.
• The vesting schedules and performance metrics used in BioLife Solutions' plans are generally in line with industry standards.

Stakeholder Impact

• Shareholders may view the stock grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

BioLife Solutions, BLFS, Aby J. Mathew, restricted stock, Form 4, EVP, Chief Scientific Officer, shareholder return, stock grants, beneficial ownership